The rise of copyright’s blockbuster initially sparked a boom for the drug industry, but recent changes present a uncertain outlook for shareholders. Off-patent versions are reducing profits, and ongoing litigation https://theobmpw553150.tblogz.com/the-blue-pill-and-pharma-a-risky-play-54375752